645
Views
10
CrossRef citations to date
0
Altmetric
Research Article

A simple pharmacokinetic model of alendronate developed using plasma concentration and urine excretion data from healthy men

, , , , , , & show all
Pages 1325-1329 | Received 02 Oct 2012, Accepted 17 Jun 2013, Published online: 25 Jul 2013

References

  • Olszynski WP, Davison KS. Alendorate for the treatment of osteoporosis in men. Drug Eval 2008;9:491–8
  • Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996;18:75–85
  • Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998;19:80–100
  • Porras GA, Holland DS, Gertz JB. Pharmacokinetics of alendronate. Clin Pharmacokinet 1999;36:315–28
  • Yun MH, Woo JS, Kwon KI. Bioequivalence and pharmacokinetics of 70 mg alendronate sodium tablets by measuring alendronate in plasma. Arch Pharm Res 2006;29:328–32
  • Yun MH, Kwon KI. High-performance liquid chromatography method for determining alendronate sodium in human plasma by detecting fluorescence: application to a pharmacokinetic study in humans. J Pharm Biomed Anal 2006;40:168–72
  • Cremers SC, Pillai G, Papapoulos SE. Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 2005;44:551–70
  • Kang SH, Hwang JS, Park SJ, Kim KC. HPLC method validation and pharmacokinetic study of alendronate sodium in human urine with fluorescence detection. J Liq Chrom Relat Tech 2006;29:1589–600
  • Gupta KV, Jain R, Sharma S, et al. Quantitative determination of alendronate in human urine. Int J Electrochem Sci 2012;7:569–87
  • D’argenio ZD, Schumitzky A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed 1979;9:115–34
  • Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41
  • DiPiro TJ, Spruill JW, Wade EW, et al. Two-compartment models. Concepts in clinical pharmacokinetics. 5th ed. Bethesda (MD): American Society of Health-System Pharmacists; 2010:73–5
  • Cremers MLCS, Hogezand VR, Banffer D, et al. Absorption of the oral bisphosphonate alendronate in osteoporotic patients with Crohn's disease. Osteoporos Int 2005;16:1727–30
  • Mitchell DY, Eusebio RA, Dunlap LE, et al. Risedronate gastrointestinal absorption is independent of site and rate of administration. Pharm Res 1998;15:228–332
  • DeWolf AM, Fragen RJ, Avram MJ, et al. The pharmacokinetics of dexmedetomidine in volunteers with severe renal impairment. Anesth Analg 2001;93:1205–9
  • Swan KS, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000;20:318–29
  • Kanis AJ, Delmas P, Burckhardt P, et al. Guidelines for diagnosis and management of osteoporosis. Osteoporos Int 1997;7:390–406
  • Stepensky D, Kleinberg L, Hoffman A. Bone as an effect compartment: models for uptake and release of drugs. Clin Pharmacokinet 2003;42:863–81

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.